Related Experiment Videos
Redefining heart failure: the utility of genomics
Mark P Donahue1, Douglas A Marchuk, Howard A Rockman
1Duke University Medical Center Department of Medicine, Division of Cardiovascular Medicine, Durham, North Carolina 27710, USA. mark.donahue@duke.edu
Journal of the American College of Cardiology
|October 3, 2006
Summary
Genomic information is transforming heart failure diagnosis, prognosis, and treatment. This review explores how genomic data can redefine cardiomyopathies and guide clinical management.
Area of Science:
- Cardiovascular Medicine
- Genomics
- Translational Medicine
Background:
- Genomic technologies offer new insights into heart failure.
- Genomic information is increasingly impacting disease understanding, diagnosis, prognosis, and treatment response.
- Lessons from oncology highlight the reciprocal relationship between clinical application and laboratory research.
Purpose of the Study:
- To review current genomic evidence relevant to heart failure.
- To explore how genomic information can redefine the understanding of cardiomyopathies.
- To discuss the integration of genomic data into the evaluation and management of cardiomyopathies.
Main Methods:
- Review of existing genomic studies and literature.
- Analysis of how genomic data can inform diagnostic and prognostic models.
- Exploration of translational medicine principles in heart failure research.
Main Results:
- Genomic data has the potential for clinical utility, such as predicting treatment response.
- Genomic insights can drive further laboratory research, aiding new drug discovery.
- Genomic evidence is beginning to reshape the approach to heart failure diagnosis and management.
Conclusions:
- Genomic information is crucial for advancing heart failure care.
- Redefining cardiomyopathies through genomic data is a key area of development.
- Integrating genomic insights into clinical practice is essential for personalized heart failure management.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...